title: p-Hydroxyamphetamine causes prepulse inhibition disruptions in mice: contribution of dopamine neurotransmission.
abstract: It is well known that amphetamine induces disrupted prepulse inhibition (PPI) in humans and rodents. We have previously reported that intracerebroventricular (i.c.v.) administration of p-hydroxyamphetamine (p-OHA) induces multiple behavioral responses, such as increased locomotor activity and head-twitch response in rodents. To reveal the characteristics of p-OHA on sensorimotor function in rodents, herein we tested the effects of p-OHA on PPI in mice. i.c.v. administration of p-OHA dose-dependently induced PPI disruptions for all prepulse intervals tested. This effect of p-OHA on PPI was attenuated by pretreatment with haloperidol or clozapine. p-OHA-induced PPI disruptions were also attenuated by pretreatment with L-741,626 (a selective D(2) receptor antagonist), L-745,870 (a selective D(4) receptor antagonist) or 6-hydroxydopamine (a neurotoxin which targets DA-containing neurons), but not by SCH 23390 (a selective D(1) receptor antagonist), eticlopride (a D(2)/D(3) receptor antagonist) or GBR 12909 (a DA-reuptake inhibitor). These results indicate that selective blockade of either the D(2) or D(4) receptor subtype may prevent disruption of PPI induced by p-OHA via presynaptic DA release.
authors.affiliation: Department of Pharmacology, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Onogi
authors.forename: Osamu
authors.initials: O
authors.lastname: Nakagawasai
authors.forename: Koichi
authors.initials: K
authors.lastname: Tan-No
authors.forename: Satoru
authors.initials: S
authors.lastname: Mitazaki
authors.forename: Atsushi
authors.initials: A
authors.lastname: Sato
authors.forename: Kota
authors.initials: K
authors.lastname: Nakaya
authors.forename: Fukie
authors.initials: F
authors.lastname: Niijima
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Arai
authors.forename: Tsuneaki
authors.initials: T
authors.lastname: Kikuchi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Tadano
mesh_terms: D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D003024:Clozapine / Q000494:pharmacology; D004298:Dopamine / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D006220:Haloperidol / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D016627:Oxidopamine / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D011725:Pyridines; D011758:Pyrroles; D013216:Reflex, Startle / Q000187:drug effects; D012457:Salicylamides / Q000494:pharmacology; D055139:Sensory Gating / Q000187:drug effects*; D013566:Sympathomimetics / Q000008:administration & dosage / Q000494:pharmacology*; D009435:Synaptic Transmission / Q000187:drug effects*; D010136:p-Hydroxyamphetamine / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: C099630:3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine; D001552:Benzazepines; D007211:Indoles; D010879:Piperazines; D010880:Piperidines; D011725:Pyridines; D011758:Pyrroles; C534628:SCH 23390; D012457:Salicylamides; D013566:Sympathomimetics; C104750:3-(4-(4-chlorophenyl-4-hydroxypiperidino)methyl)indole; D016627:Oxidopamine; C043425:vanoxerine; D010136:p-Hydroxyamphetamine; D003024:Clozapine; D006220:Haloperidol; C045989:eticlopride; D004298:Dopamine